S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
S&P 500   4,587.91 (+0.80%)
DOW   35,672.47 (+0.51%)
QQQ   382.70 (+0.71%)
AAPL   152.40 (+2.38%)
MSFT   321.93 (-0.38%)
FB   313.20 (+0.31%)
GOOGL   2,908.00 (-0.56%)
TSLA   1,061.68 (+2.30%)
AMZN   3,418.31 (+0.76%)
NVDA   247.45 (+1.20%)
BABA   169.73 (+0.30%)
NIO   39.62 (+0.79%)
CGC   13.08 (+2.35%)
GE   104.41 (+0.54%)
AMD   122.84 (+0.46%)
MU   69.34 (+1.61%)
T   25.53 (+1.88%)
F   16.94 (+9.22%)
ACB   6.95 (+1.61%)
DIS   169.99 (+0.26%)
PFE   43.21 (+0.56%)
BA   206.66 (+0.02%)
AMC   35.90 (+3.28%)
NASDAQ:ELYM

Eliem Therapeutics Stock Forecast, Price & News

$17.94
-0.22 (-1.21 %)
(As of 10/28/2021 10:30 AM ET)
Add
Compare
Today's Range
$17.94
$18.07
50-Day Range
$13.77
$28.61
52-Week Range
$13.51
$29.69
Volume
17 shs
Average Volume
195,467 shs
Market Capitalization
$476.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive ELYM News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Eliem Therapeutics logo

About Eliem Therapeutics

Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELYM
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$476.27 million
Next Earnings Date
12/13/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.83 out of 5 stars

Medical Sector

766th out of 1,372 stocks

Pharmaceutical Preparations Industry

372nd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Eliem Therapeutics (NASDAQ:ELYM) Frequently Asked Questions

Is Eliem Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eliem Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Eliem Therapeutics stock.
View analyst ratings for Eliem Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Eliem Therapeutics?

Wall Street analysts have given Eliem Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Eliem Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Eliem Therapeutics' next earnings date?

Eliem Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, December 13th 2021.
View our earnings forecast for Eliem Therapeutics
.

How were Eliem Therapeutics' earnings last quarter?

Eliem Therapeutics Inc (NASDAQ:ELYM) released its earnings results on Monday, September, 13th. The company reported ($3.11) EPS for the quarter, missing the Zacks' consensus estimate of ($2.37) by $0.74.
View Eliem Therapeutics' earnings history
.

What price target have analysts set for ELYM?

4 equities research analysts have issued twelve-month price objectives for Eliem Therapeutics' shares. Their forecasts range from $32.00 to $35.00. On average, they anticipate Eliem Therapeutics' stock price to reach $33.33 in the next year. This suggests a possible upside of 83.6% from the stock's current price.
View analysts' price targets for Eliem Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Eliem Therapeutics IPO?

(ELYM) raised $75 million in an IPO on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

What is Eliem Therapeutics' stock symbol?

Eliem Therapeutics trades on the NASDAQ under the ticker symbol "ELYM."

When did Eliem Therapeutics' quiet period expire?

Eliem Therapeutics' quiet period expired on Monday, September 20th. Eliem Therapeutics had issued 6,400,000 shares in its public offering on August 10th. The total size of the offering was $80,000,000 based on an initial share price of $12.50. During Eliem Therapeutics' quiet period, insiders and underwriters involved in the IPO were restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Eliem Therapeutics?

Shares of ELYM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eliem Therapeutics' stock price today?

One share of ELYM stock can currently be purchased for approximately $18.16.

How much money does Eliem Therapeutics make?

Eliem Therapeutics has a market capitalization of $482.11 million.

How many employees does Eliem Therapeutics have?

Eliem Therapeutics employs 2,021 workers across the globe.

What is Eliem Therapeutics' official website?

The official website for Eliem Therapeutics is www.eliemtx.com.

How can I contact Eliem Therapeutics?

The company can be reached via phone at 425-276-2300 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.